Next Article in Journal
Recent Developments Centered on Orally Active Iron Chelators
Previous Article in Journal
Reference Intervals for Acetylated Fetal Hemoglobin in Healthy Newborns
Thalassemia Reports is published by MDPI from Volume 12 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Iron Chelating Agents for Iron Overload Diseases

Department of Chemical and Geological Sciences, University of Cagliari, I-09042 Monserrato, Italy
Department of Chemistry and Pharmacy, University of Sassari, Sassari, Italy
Author to whom correspondence should be addressed.
Thalass. Rep. 2014, 4(2), 2046;
Submission received: 30 October 2013 / Revised: 22 June 2014 / Accepted: 27 July 2014 / Published: 29 September 2014


Although iron is an essential element for life, an excessive amount may become extremely toxic both for its ability to generate reactive oxygen species, and for the lack in humans of regulatory mechanisms for iron excretion. Chelation therapy has been introduced in clinical practice in the seventies of last century to defend thalassemic patients from the effects of iron overload and, in spite of all its limitations, it has dramatically changed both life expectancy and quality of life of patients. It has to be considered that the drugs in clinical use present some disadvantages too, this makes urgent new more suitable chelating agents. The requirements of an iron chelator have been better and better defined over the years and in this paper they will be discussed in detail. As a final point the most interesting ligands studied in the last years will be presented.
Keywords: iron chelator; β-thalassemia; pFe; hydroxypyridinone; deferoxamine iron chelator; β-thalassemia; pFe; hydroxypyridinone; deferoxamine

Share and Cite

MDPI and ACS Style

Crisponi, G.; Nurchi, V.M.; Zoroddu, M.A. Iron Chelating Agents for Iron Overload Diseases. Thalass. Rep. 2014, 4, 2046.

AMA Style

Crisponi G, Nurchi VM, Zoroddu MA. Iron Chelating Agents for Iron Overload Diseases. Thalassemia Reports. 2014; 4(2):2046.

Chicago/Turabian Style

Crisponi, Guido, Valeria Marina Nurchi, and Maria Antonietta Zoroddu. 2014. "Iron Chelating Agents for Iron Overload Diseases" Thalassemia Reports 4, no. 2: 2046.

Article Metrics

Back to TopTop